

# CITATION REPORT

List of articles citing

Des-?-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma

DOI: 10.1159/000327570

Digestive Diseases, 2011, 29, 321-5.

**Source:** <https://exaly.com/paper-pdf/52016228/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
49	Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. <i>Digestive Diseases</i> , <b>2011</b> , 29, 289-302	3.2	30
48	Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. <i>Digestive Diseases</i> , <b>2011</b> , 29, 273-7	3.2	19
47	Evaluation of the mRECIST and $\alpha$ -fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. <i>Oncology</i> , <b>2012</b> , 83, 192-200	3.6	59
46	Hepatocellular Carcinoma Diagnostics, Treatments and Potential Theragnostics in the Asia-Pacific. <i>Current Pharmacogenomics and Personalized Medicine</i> , <b>2012</b> , 10, 159-169	0.4	
45	Evaluation of the effect of sorafenib using serum NX-des- $\alpha$ -carboxyprothrombin in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , <b>2013</b> , 43, 1064-70	5.1	12
44	New serum markers of hepatocellular carcinoma. <i>Seminars in Oncology</i> , <b>2012</b> , 39, 434-9	5.5	62
43	Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. <i>Liver Cancer</i> , <b>2012</b> , 1, 62-70	9.1	88
42	Médecine personnalisée en oncologie digestive. <b>2013</b> ,		
41	Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. <i>Therapeutic Advances in Gastroenterology</i> , <b>2013</b> , 6, 447-58	4.7	23
40	Novel des- $\alpha$ -carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2013</b> , 28, 1348-55	4	15
39	Early increase in $\alpha$ -fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2013</b> , 25, 683-9	2.2	60
38	Sorafenib in the Continuum of Care for Hepatocellular Carcinoma: Challenges in Defining Optimal Practice. <b>2013</b> ,		
37	Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan. <i>Oncology</i> , <b>2014</b> , 87 Suppl 1, 104-9	3.6	15
36	Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling. <i>Molecular and Cellular Proteomics</i> , <b>2014</b> , 13, 1429-38	7.6	49
35	Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. <i>Hepatology Research</i> , <b>2014</b> , 44, 1268-76	5.1	21
34	Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>Digestive Diseases</i> , <b>2014</b> , 32, 705-10	3.2	13
33	Biomarkers and Personalized Sorafenib Therapy. <i>Liver Cancer</i> , <b>2014</b> , 3, 399-404	9.1	14

32	Challenges of Clinical Research on Hepatocellular Carcinoma. <i>Digestive Diseases</i> , <b>2015</b> , 33, 780-90	3.2	3
31	Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma. <i>Digestive Diseases</i> , <b>2015</b> , 33, 771-9	3.2	62
30	Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy. <i>Journal of Digestive Diseases</i> , <b>2015</b> , 16, 537-40	3.3	8
29	Impact of more detailed categorization of shrinkage or progression ratio at initial imaging response after sorafenib treatment in advanced hepatocellular carcinoma patients. <i>OncoTargets and Therapy</i> , <b>2015</b> , 8, 3193-202	4.4	1
28	An interim safety analysis of hepatocellular carcinoma patients administrating oral vitamin K with or without sorafenib. <i>Korean Journal of Hepato-biliary-pancreatic Surgery</i> , <b>2015</b> , 19, 1-5		10
27	New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions. <i>Hepatology Research</i> , <b>2015</b> , 45, E1-E11	5.1	53
26	Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells. <i>Cellular Physiology and Biochemistry</i> , <b>2015</b> , 35, 201-12	3.9	13
25	Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. <i>Liver Cancer</i> , <b>2015</b> , 4, 39-50	9.1	149
24	Systemic therapy of hepatocellular carcinoma: current and promising. <i>Clinics in Liver Disease</i> , <b>2015</b> , 19, 421-32	4.6	31
23	Early evaluation of response to sorafenib for hepatocellular carcinoma by duplex Doppler ultrasonography. <i>Hepatology Research</i> , <b>2015</b> , 45, 976-985	5.1	2
22	Advanced Stage Hepatocellular Carcinoma with Multiple Metastasis and Vascular Thrombosis: A Case of Complete Response to Sorafenib. <i>Acta Medica Portuguesa</i> , <b>2016</b> , 29, 139-142	1.4	5
21	Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib. <i>Journal of Gastrointestinal Oncology</i> , <b>2016</b> , 7, E36-40	2.8	5
20	Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience. <i>Digestive Diseases</i> , <b>2017</b> , 35, 611-617	3.2	11
19	Effect of sorafenib on des- $\gamma$ -carboxyprothrombin secretion by a human hepatocellular carcinoma cell line. <i>Oncology Letters</i> , <b>2017</b> , 14, 2170-2176	2.6	2
18	Changes in plasma interleukin-8 and tumor necrosis factor- $\alpha$ levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 82, 857-864	3.5	3
17	Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion. <i>Hepatology Research</i> , <b>2019</b> , 49, 594-599	5.1	22
16	Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. <i>Cells</i> , <b>2020</b> , 9,	7.9	59
15	Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment. <i>Cancers</i> , <b>2020</b> , 12,	6.6	11

14	Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma. <i>Reports</i> , <b>2021</b> , 4, 25	0.4	
13	Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
12	The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. <i>PLoS ONE</i> , <b>2016</b> , 11, e0146456	3.7	12
11	A case of hepatopulmonary syndrome derived from nonalcoholic fatty liver disease with severe liver fibrosis, in which hypoxia could be recovered by the improvement of liver fibrosis. <i>Acta Hepatologica Japonica</i> , <b>2014</b> , 55, 479-487	0.3	2
10	Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 4151-9	5.6	26
9	Biological features and biomarkers in hepatocellular carcinoma. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 2020-8	3.4	12
8	Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 2245-63	3.4	8
7	Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma. <i>Gut and Liver</i> , <b>2019</b> , 13, 342-348	4.8	16
6	Biomarqueurs prédictifs d'efficacité <b>2013</b> , 289-304		
5	Hepatic arterial infusion chemotherapy and sorafenib for the treatment of advanced hepatocellular carcinoma patients. <i>Journal of Microwave Surgery</i> , <b>2014</b> , 32, 13-18	0	
4	Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , <b>2021</b> , 1-10	3.6	1
3	The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study. <i>Oncotarget</i> , <b>2021</b> , 12, 2338-2350	3.3	1
2	Early Predictive Value of Circulating Biomarkers for Sorafenib in Advanced Hepatocellular Carcinoma.. <i>Expert Review of Molecular Diagnostics</i> , <b>2022</b> ,	3.8	0
1	Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response. 12,		0